SSY GROUP(02005),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02005 SSY GROUP

Not Yet Opened 04-29 16:08:37

2.360

+0.010

+0.43%

High2.360	Low2.340	Vol8.09M
Open2.350	D1 Closing2.350	Amplitude0.85%
Mkt Cap6.84B	Tradable Cap6.84B	Total Shares2.90B
T/O18.99M	T/O Rate0.28%	Tradable Shares2.90B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"SSY GROUP","latestPrice":2.36,"timestamp":1777450117003,"preClose":2.35,"halted":0,"volume":8086000,"delay":0,"changeRate":0.004255319148936079,"floatShares":2899000000,"shares":2899000000,"eps":0.1605,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"04-29 16:08:37","open":2.35,"high":2.36,"low":2.34,"amount":18985800,"amplitude":0.008511,"askPrice":2.36,"askSize":114000,"bidPrice":2.34,"bidSize":578000,"shortable":3,"etf":0,"ttmEps":0.1605,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777512600000},"marketStatusCode":0,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.35,"dividendRate":0.033898,"openAndCloseTimeList":[[1777426200000,1777435200000],[1777438800000,1777449600000]],"volumeRatio":1.2902645186079928,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"1190248585","title":"SSY GROUP Granted Pharmaceutical Production Registration Certificate for Diltiazem Hydrochloride Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1190248585","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190248585?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:08","pubTimestamp":1777262901,"startTime":"0","endTime":"0","summary":"SSY GROUP (02005) has announced that the group has obtained a pharmaceutical production registration certificate from China's National Medical Products Administration for Diltiazem Hydrochloride for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124471122","title":"SSY Group Secures NMPA Production Approvals for Diltiazem and Propranolol Injections","url":"https://stock-news.laohu8.com/highlight/detail?id=1124471122","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124471122?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:03","pubTimestamp":1777262624,"startTime":"0","endTime":"0","summary":"SSY Group Limited announced on 27 April 2026 that China’s National Medical Products Administration (NMPA) has granted production and registration approvals for two cardiovascular therapies—Diltiazem...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630359941","title":"SSY Group wins China NMPA approval for diltiazem injection###","url":"https://stock-news.laohu8.com/highlight/detail?id=2630359941","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630359941?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:02","pubTimestamp":1777262532,"startTime":"0","endTime":"0","summary":"SSY Group secured China NMPA production and registration clearance for Diltiazem Hydrochloride for Injection , treated as having passed consistency evaluation.NMPA also granted production and registration approval for Propranolol Hydrochloride Injection , also treated as having passed consistency evaluation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL86p3xL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630359956","title":"SSY Group - Obtains Nmpa Approval for Diltiazem Hydrochloride for Injection (10Mg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630359956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630359956?lang=en_us&edition=fundamental","pubTime":"2026-04-27 12:01","pubTimestamp":1777262487,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41803I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181932330","title":"SSY Group releases 2025 Annual Report, Circular and Proxy Form; shareholders invited to choose digital or print delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=1181932330","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181932330?lang=en_us&edition=fundamental","pubTime":"2026-04-21 17:03","pubTimestamp":1776762187,"startTime":"0","endTime":"0","summary":"On 22 April 2026, SSY Group Limited issued a formal notice confirming that the English and Chinese versions of its 2025 Annual Report, accompanying Circular and Proxy Form (collectively, the “Current...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894020","title":"SSY Group Gets Bulk Drug Approval for Edema Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894020","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629894020?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:54","pubTimestamp":1776761694,"startTime":"0","endTime":"0","summary":"SSY Group's  furosemide was approved for registration by China's National Medical Products Administration to become a bulk drug for preparation on the market, according to a Tuesday Hong Kong bourse filing.The product is mainly used to treat various diseases with edema, hypertension, hyperkalemia and hypercalcemia.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02005","LU2460026573.USD","SSY","BK4185","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119870424","title":"石四药集团2025年业绩：营收与净利双降，核心产品持续发力","url":"https://stock-news.laohu8.com/highlight/detail?id=1119870424","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119870424?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:54","pubTimestamp":1776761690,"startTime":"0","endTime":"0","summary":"石四药集团在其2025年年度报告中披露，公司于年内在政策与市场竞争愈发激烈的环境下，整体业务出现显著下滑。按人民币计，全年收入约为38.12亿元，同比下降27.6%；折算港币约为41.65亿港元，同比下降约27.8%。集团同时公布，年内净利润约为4.84亿港元，同比减少55.1%，其中股东应占利润约为4.71亿港元，同比下降55.6%。董事会宣派每股0.03港元末期股息，并使全年股息总额达每股0....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"石四药集团2025年业绩：营收与净利双降，核心产品持续发力","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629895450","title":"SSY Group announces annual general meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2629895450","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629895450?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:42","pubTimestamp":1776760978,"startTime":"0","endTime":"0","summary":"SSY Group schedules annual general meeting in Hong Kong on May 15, 2026.Shareholders will vote on adoption of FY2025 audited financial statements.Resolutions include re-election of directors, auditor reappointment, and authorization to set directors’ remuneration.Company seeks approval for final dividend of HK$ 0.03 per share for FY2025.Mandates to issue shares up to 20%, repurchase shares up to 10%, and extend issuance mandate by shares repurchased will be put to a vote.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 21, 2026, and is solely responsible for the infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL8sPV8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629898940","title":"SSY Group publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629898940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629898940?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:38","pubTimestamp":1776760715,"startTime":"0","endTime":"0","summary":"SSY Group published its 2025 annual report, highlighting weaker operating conditions as demand softened and procurement-driven pricing pressure intensified.Performance deteriorated across core IV infusion solutions, with volume down 24.5% and revenue down 33.5%.Ampoule injection sales volume rose 10.4%, but revenue fell 42.6% on lower average selling prices.Oral preparations expanded in volume, up 15%, supported by broader tender participation and deeper ties with large pharmacy chains.R&D pipeline progressed, with 110 production approvals and Type I innovative drug SYN045 moving through Phase I trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL4jXSPl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188296949","title":"SSY Group Receives NMPA Approval for Furosemide as API in Marketed Formulations","url":"https://stock-news.laohu8.com/highlight/detail?id=1188296949","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188296949?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:36","pubTimestamp":1776760584,"startTime":"0","endTime":"0","summary":"SSY GROUP (02005) announced that its Furosemide has been approved by the National Medical Products Administration (NMPA) for registration as an active pharmaceutical ingredient (API) intended for use...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629086273","title":"SSY Group - Furosemide Obtains Nmpa Approval for Registration as Bulk Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2629086273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629086273?lang=en_us&edition=fundamental","pubTime":"2026-04-21 16:31","pubTimestamp":1776760310,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN414092:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165925944","title":"SSY Group secures NMPA production approvals for Multiple Electrolytes Injection and Metoclopramide Hydrochloride Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1165925944","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165925944?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:43","pubTimestamp":1775796192,"startTime":"0","endTime":"0","summary":"SSY Group Limited announced that China’s National Medical Products Administration has approved both the drug production and registration of two type 3 chemical injections—Multiple Electrolytes,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626165112","title":"SSY Group Receives Chinese Regulatory Nod for Two Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2626165112","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626165112?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:42","pubTimestamp":1775796147,"startTime":"0","endTime":"0","summary":"SSY Group  said it received Chinese regulatory approvals for drug production and registration for two products, according to a Hong Kong bourse filing Friday.The approvals cover a combination injection of electrolytes, sodium acetate and glucose to treat dehydration when oral administration is not possible, and a metoclopramide hydrochloride injection to treat vomiting.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","LU2460026573.USD","02005","BK4185","SSY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191811634","title":"SSY GROUP Secures Manufacturing Approvals for Two Injectable Medications","url":"https://stock-news.laohu8.com/highlight/detail?id=1191811634","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191811634?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:18","pubTimestamp":1775794696,"startTime":"0","endTime":"0","summary":"SSY GROUP (02005) has announced that the group has obtained drug manufacturing registration approvals from China's National Medical Products Administration for Compound Sodium Acetate Electrolyte and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626416314","title":"SSY Group - Obtains Nmpa Approvals for Two Injection Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2626416314","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626416314?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:04","pubTimestamp":1775793844,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40S19E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626116312","title":"SSY Group - Products Incldue Multiple Electrolytes, Sodium Acetate and Glucose Injection and Metoclopramide Hydrochloride Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2626116312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626116312?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:04","pubTimestamp":1775793844,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nFWN40S19E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626163142","title":"SSY Group wins China NMPA approvals for multiple electrolytes and metoclopramide injections","url":"https://stock-news.laohu8.com/highlight/detail?id=2626163142","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626163142?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:03","pubTimestamp":1775793831,"startTime":"0","endTime":"0","summary":"SSY Group secured China NMPA production and registration clearances for Multiple Electrolytes, Sodium Acetate and Glucose Injection in 250 ml and 500 ml formats.Regulator also granted production and registration approval for Metoclopramide Hydrochloride Injection at 2 ml:10 mg.SSY said both products are type 3 chemical drugs that passed China consistency evaluation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDLb1jryC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624563760","title":"Asian Market Spotlight: Promising Penny Stocks For April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2624563760","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624563760?lang=en_us&edition=fundamental","pubTime":"2026-04-03 12:05","pubTimestamp":1775189114,"startTime":"0","endTime":"0","summary":"As the Asian markets navigate through geopolitical tensions and energy market volatility, investors are keenly watching for opportunities that can weather these challenges. Penny stocks, though often seen as speculative, can offer unique growth potential when supported by strong financials. In this article, we explore several promising penny stocks in Asia that may combine value with long-term potential amidst current market conditions.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4444000-choice2-main-header/1585186827172"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/retail/hkg-178/sa-sa-international-holdings-shares/news/asian-market-spotlight-promising-penny-stocks-for-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/retail/hkg-178/sa-sa-international-holdings-shares/news/asian-market-spotlight-promising-penny-stocks-for-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1525","LU0620787316.HKD","SGXZ27511609.SGD","LU0516423091.SGD","BK8040","SGXZ58947870.SGD","SGXZ43160589.SGD","LU0516422440.USD","SG9999004360.SGD","SG9999013460.SGD","02005","LU0082770016.SGD","SG9999014492.USD","LU0979878070.USD","00178","SG9999013478.USD","SG9999013486.USD","BK6065","BK6504","SG9999014484.SGD","SG9999000343.SGD","SG9999002679.SGD","BK1224","BK1577","LU0516422952.EUR","SG9999016042.SGD","LU1242518857.USD","SG9999003826.SGD","00241","SGXZ24219693.SGD","LU0082770016.USD","BK1602","LU0516422366.SGD","BK1502","LU0164939612.USD","BK6081","LU1242518931.SGD","LU0516423174.USD","SG9999000475.SGD","BK1601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138010297","title":"SSY Group Keeps Capital Structure Unchanged and Confirms Public Float Compliance for March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1138010297","media":"Bulletin Express","labels":["shareholding","SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138010297?lang=en_us&edition=fundamental","pubTime":"2026-04-01 17:47","pubTimestamp":1775036842,"startTime":"0","endTime":"0","summary":"SSY Group Limited filed its FF301 Monthly Return for the period ended 31 March 2026, showing a stable share capital structure with full adherence to Hong Kong Listing Rules. The authorised share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623930884","title":"SSY Group Gets Bulk Drug Approval for Arthritis Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2623930884","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623930884?lang=en_us&edition=fundamental","pubTime":"2026-03-31 13:48","pubTimestamp":1774936127,"startTime":"0","endTime":"0","summary":"SSY Group's (HKG:2005) Upadacitinib was approved for registration by China's National Medical Products Administration to become a bulk drug for preparation on the market, according to a Tuesday Hong Kong bourse filing.The product is mainly used to treat rheumatoid arthritis and Crohn's disease.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2460026573.USD","02005","SSY","BK4185","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":-0.0126},{"period":"1month","weight":-0.0598},{"period":"3month","weight":-0.2159},{"period":"6month","weight":-0.2387},{"period":"1year","weight":-0.1598},{"period":"ytd","weight":-0.1661}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.055},{"period":"3month","weight":-0.0664},{"period":"6month","weight":0.0079},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008314},{"month":2,"riseRate":0.52381,"avgChangeRate":0.02049},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079064},{"month":4,"riseRate":0.47619,"avgChangeRate":0.032171},{"month":5,"riseRate":0.45,"avgChangeRate":0.00985},{"month":6,"riseRate":0.5,"avgChangeRate":0.067908},{"month":7,"riseRate":0.35,"avgChangeRate":-0.027819},{"month":8,"riseRate":0.35,"avgChangeRate":-0.017769},{"month":9,"riseRate":0.3,"avgChangeRate":-0.04678},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001982},{"month":11,"riseRate":0.65,"avgChangeRate":0.086372},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009169}],"exchange":"SEHK","name":"SSY GROUP","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SSY GROUP(02005),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SSY GROUP(02005) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SSY GROUP,02005,SSY GROUP股票,SSY GROUP股票老虎,SSY GROUP股票老虎国际,SSY GROUP行情,SSY GROUP股票行情,SSY GROUP股价,SSY GROUP股市,SSY GROUP股票价格,SSY GROUP股票交易,SSY GROUP股票购买,SSY GROUP股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SSY GROUP(02005),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SSY GROUP(02005) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}